Last Updated: November 16, 2026

Investigational Drug Information for Sabarubicin

« Back to Dashboard


What is the drug development status for Sabarubicin?

Sabarubicin is an investigational drug.

There have been 3 clinical trials for Sabarubicin. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2001.

The most common disease conditions in clinical trials are Neoplasms, Prostatic Neoplasms, and Testicular Neoplasms. The leading clinical trial sponsors are European Organisation for Research and Treatment of Cancer - EORTC and [disabled in preview].

Recent Clinical Trials for Sabarubicin
TitleSponsorPhase
MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone TherapyEuropean Organisation for Research and Treatment of Cancer - EORTCPhase 2
MEN-10755 in Treating Patients With Solid TumorsEuropean Organisation for Research and Treatment of Cancer - EORTCPhase 1
MEN-10755 in Treating Adults With Recurrent or Refractory Solid TumorsEuropean Organisation for Research and Treatment of Cancer - EORTCPhase 1

See all Sabarubicin clinical trials

Clinical Trial Summary for Sabarubicin

Top disease conditions for Sabarubicin
Top clinical trial sponsors for Sabarubicin

See all Sabarubicin clinical trials

Sabarubicin Development Update and Market Projection

Last updated: September 29, 2026

Sabarubicin, also known as MEN 10755, is an experimental anthracycline developed primarily for solid tumors, including non-small-cell lung cancer (NSCLC), small-cell lung cancer and breast cancer. Its clinical program reached early- to mid-stage development but has not produced a marketed medicine. Public evidence does not establish an active late-stage program, current regulatory review, an approved indication, or a credible near-term launch date. The commercial outlook is therefore low without a new sponsor, materially differentiated efficacy data or a development strategy focused on a narrowly defined oncology population.

What is sabarubicin and how does it work?

Sabarubicin is a semisynthetic anthracycline designed to retain antitumor activity while reducing some liabilities associated with doxorubicin and related agents. The compound is also identified as MEN 10755.

Its pharmacologic activity is associated with DNA intercalation and inhibition of topoisomerase II, mechanisms shared with established anthracyclines. The development rationale centered on potential activity against solid tumors and a possible improvement in the therapeutic index, particularly cardiac safety.

Attribute Sabarubicin
Development code MEN 10755
Drug class Anthracycline
Primary mechanism DNA intercalation and topoisomerase II inhibition
Development stage reached Early- to mid-stage clinical development
Approved indication None identified
FDA approval None identified
Commercial status Not marketed
Principal historical developer Menarini-related development organizations
Key development issue Limited evidence of durable differentiation against established chemotherapy

Preclinical and early clinical publications described sabarubicin as a candidate with antitumor activity and a potentially different toxicity profile from doxorubicin. Those characteristics were not sufficient, based on the public development record, to produce an approved product. (Cvitkovic et al., 2002; ClinicalTrials.gov, n.d.)

What is the current development status of sabarubicin?

Sabarubicin does not appear to have an active registration-stage program or an FDA-approved development pathway. Publicly available clinical information places the program in completed or inactive early- and mid-stage studies rather than in an ongoing pivotal trial.

Historical studies evaluated sabarubicin in advanced solid tumors. Research areas included:

  • NSCLC
  • Small-cell lung cancer
  • Breast cancer
  • Other advanced or refractory solid tumors

The program appears to have investigated sabarubicin as monotherapy and in combination regimens, including platinum-based chemotherapy. The clinical strategy reflected the market environment of the late 1990s and early 2000s, when new anthracyclines were often assessed as alternatives to doxorubicin or as components of combination chemotherapy.

No public evidence establishes that sabarubicin has entered a modern confirmatory trial supported by a current commercial sponsor. Its development status is therefore best classified as inactive, discontinued or commercially dormant unless a sponsor has restarted the program outside the principal public databases.

Sabarubicin development timeline

Period Development event Commercial significance
Late 1990s to early 2000s Preclinical and first-in-human development of MEN 10755 Established pharmacology and initial tolerability
Early 2000s Clinical evaluation in advanced solid tumors Generated efficacy and safety data but no approval
Mid-2000s Studies in lung cancer and other tumor types Tested the candidate against established chemotherapy
Later period No clearly documented pivotal registration program Reduced probability of independent commercialization
Current public record No approved product or active late-stage program identified Near-term revenue opportunity is limited

ClinicalTrials.gov records and published oncology studies are the primary public sources for the historical program. They do not establish a current FDA filing, European marketing authorization application or active Phase III program. (ClinicalTrials.gov, n.d.; European Medicines Agency, n.d.)

What cancer indications were studied for sabarubicin?

Non-small-cell lung cancer

NSCLC was one of the most commercially relevant areas investigated for sabarubicin. The candidate was evaluated in advanced disease, including combination approaches with platinum chemotherapy.

The competitive environment has changed substantially since those studies. Modern NSCLC treatment is organized around histology, biomarker status and line of therapy. Targeted therapies for EGFR, ALK, ROS1, KRAS G12C, MET and other alterations compete with immunotherapies and antibody-drug conjugates. A conventional anthracycline would need a clear survival, response-rate or safety advantage to regain development relevance.

Sabarubicin lacks publicly established data demonstrating superiority to platinum doublets, immune checkpoint inhibitor combinations or targeted treatments in biomarker-selected NSCLC.

Small-cell lung cancer

Small-cell lung cancer has historically provided an opportunity for cytotoxic agents because treatment options were limited. Sabarubicin was studied in this area, but the current treatment environment includes platinum-etoposide combinations, immunotherapy and later-line agents such as lurbinectedin in relevant jurisdictions.

A restart in small-cell lung cancer would require a differentiated clinical hypothesis, such as activity in platinum-resistant disease, a meaningful improvement in overall survival or a tolerability advantage over existing agents.

Breast cancer and other solid tumors

Anthracyclines remain important in selected breast-cancer settings, but the class is mature and highly competitive. Doxorubicin, epirubicin, pegylated liposomal doxorubicin and newer antibody-drug conjugates create a high evidentiary threshold for a new anthracycline.

Sabarubicin would need to demonstrate more than activity in previously treated patients. A commercially viable profile would likely require reduced cardiac toxicity, durable efficacy, a convenient dosing schedule or a combination strategy that cannot be replicated by existing anthracyclines.

What is the FDA regulatory status of sabarubicin?

Sabarubicin is not identified as an FDA-approved drug. No publicly established New Drug Application approval, Biologics License Application approval or FDA-recognized commercial label was identified for the compound.

Because sabarubicin is a small-molecule cytotoxic agent, its regulatory pathway would ordinarily require:

  1. An active Investigational New Drug application.
  2. A defined clinical development program.
  3. Adequate and well-controlled trials.
  4. Chemistry, manufacturing and controls data.
  5. A safety database sufficient for chronic oncology use.
  6. A New Drug Application and FDA review.

There is no public basis to assign sabarubicin an approval date, prescription market size or regulatory exclusivity period. Any projection that assumes an imminent FDA filing would be unsupported.

What patents protect sabarubicin?

The public commercial record does not establish a currently enforceable, commercially material patent estate for sabarubicin. Historical compound, formulation, process and use patents may have been filed during the original development period, but the available information does not support a definitive list of live patent numbers, owners, claims or expiration dates.

For a compound first developed around the turn of the century, basic composition-of-matter protection would generally face substantial age-related erosion. In the United States, a patent filed around that period could ordinarily approach or pass its 20-year term, subject to filing history, terminal disclaimers, patent-term adjustment and patent-term extension. No verified patent-term extension supporting current market exclusivity has been established.

IP category Likely historical relevance Current commercial assessment
Composition of matter Core protection for MEN 10755 Likely aged or expired, subject to verification
Salt or polymorph May protect selected solid forms Limited value without a marketed product
Formulation Could cover injectable or stability-enhanced formulations No public evidence of an active commercial formulation estate
Method of use Could cover cancer indications or combinations Value depends on enforceable claims and clinical adoption
Manufacturing process Could create technical barriers Potentially relevant to supply, but not a substitute for clinical differentiation

No reliable public evidence establishes an active Paragraph IV dispute involving an approved generic version of sabarubicin. Since the drug is not approved and not marketed, a conventional Orange Book generic-entry dispute is unlikely to be the principal near-term legal issue.

What is the Orange Book status of sabarubicin?

Sabarubicin has no established Orange Book-listed reference product. The FDA Orange Book lists approved drug products and associated patents and exclusivity information. An unapproved investigational compound does not receive ordinary Orange Book protection.

The practical consequences are significant:

  • No Orange Book-listed reference listed drug has been established.
  • No standard Abbreviated New Drug Application pathway is currently available.
  • No routine Paragraph IV challenge against an approved sabarubicin product is apparent.
  • Any future entrant would likely need to pursue an original NDA unless an approved reference product first exists.
  • Patent disputes would more likely arise from a future development program than from current generic substitution.

(Food and Drug Administration, n.d.)

When does sabarubicin lose exclusivity?

Sabarubicin has no identifiable current regulatory exclusivity period because it has not obtained marketing approval. The relevant IP question is not when an approved exclusivity period ends, but whether any historical patents remain enforceable.

Potential forms of exclusivity would include:

  • Composition-of-matter patent protection.
  • Use patents for specific cancer indications.
  • Formulation or dosing patents.
  • Orphan-drug exclusivity if a jurisdiction granted it.
  • Regulatory data exclusivity after a hypothetical approval.

No verified U.S. orphan-drug exclusivity or New Chemical Entity exclusivity has been established for sabarubicin. Any future sponsor would need to assess patent family status in the United States, Europe, Japan and other major markets before assigning economic value to the asset.

Which companies are challenging sabarubicin?

No meaningful public generic or biosimilar challenge program has been identified. Sabarubicin is a small molecule, so biosimilar competition is not applicable. If developed today, the relevant competitors would be generic anthracyclines, newer cytotoxic agents, targeted therapies, immunotherapies and antibody-drug conjugates.

Potential competitive products would vary by indication:

Indication Established or newer competitors
Breast cancer Doxorubicin, epirubicin, pegylated liposomal doxorubicin, taxanes and antibody-drug conjugates
NSCLC Platinum combinations, pembrolizumab-based regimens, targeted therapies and antibody-drug conjugates
Small-cell lung cancer Platinum-etoposide, atezolizumab, durvalumab and lurbinectedin
Refractory solid tumors Topoisomerase inhibitors, taxanes, liposomal formulations and investigational ADCs

The absence of a direct generic challenge does not indicate commercial strength. It primarily reflects the absence of an approved and marketed reference product.

How strong is the sabarubicin patent and development estate?

The estate appears weak from a commercialization perspective because the public record does not show three elements needed to support high asset value:

  1. A current patent position with clearly surviving, broad claims.
  2. An active sponsor with capital and regulatory execution capacity.
  3. Clinical evidence that differentiates sabarubicin from established and newer therapies.

The molecule may retain technical value for licensing if historical data show a clinically meaningful reduction in cardiotoxicity or activity in a resistant tumor population. The asset would be more difficult to license for broad first-line oncology use because the standard of care has advanced and anthracycline markets are heavily genericized.

What market could sabarubicin address?

A bottom-up market projection cannot be supported by approved-label sales, current pricing, prescription volume or a validated launch plan. A scenario-based assessment is more appropriate.

Downside case

The program remains inactive. Revenue is zero, and the asset has research value only.

Restart case

A sponsor licenses the compound and conducts a new Phase I or Phase Ib study in a focused population, potentially emphasizing cardiac safety or resistant disease. This path would require several years of development and substantial capital before any commercial revenue.

Success case

Sabarubicin demonstrates a clinically meaningful safety advantage and efficacy in a defined cancer population. Commercial value would still depend on the size of that population, treatment duration, reimbursement and competition from low-cost generics and newer targeted agents.

The addressable market is therefore unlikely to resemble the market for a broad first-line oncology product unless new data materially change the candidate's positioning. The most credible commercial strategy would be a niche indication with unmet need rather than an attempt to replace doxorubicin across multiple tumor types.

What licensing deals involve sabarubicin?

No current, publicly documented licensing transaction establishing an active commercialization partnership was identified. Historical development was associated with Menarini-related organizations, but the public record does not support assigning a current licensee, milestone structure, royalty rate or territory allocation.

A future transaction would likely be structured around:

  • Option-based development rights.
  • Regional licensing.
  • Milestones tied to IND activation, proof of concept and pivotal-trial initiation.
  • Low upfront consideration until new clinical data reduce development risk.
  • Rights focused on a single tumor type or biomarker-defined population.

What generic launch risks exist for sabarubicin?

The immediate generic-launch risk is low because there is no approved reference product. The long-term commercial risk from generic competition would be high if sabarubicin were approved without strong differentiation.

Key risks include:

  • Substitution by low-cost doxorubicin or epirubicin.
  • Physician familiarity with established anthracyclines.
  • Limited ability to command premium pricing.
  • Competition from liposomal delivery systems.
  • Rapid displacement by antibody-drug conjugates and immunotherapy combinations.
  • Weak negotiating leverage with hospitals and group purchasing organizations.

Manufacturing could create a secondary barrier because anthracycline production requires controlled handling, validated sterile manufacturing and management of cytotoxic waste. Those barriers are operational rather than durable market exclusivity and would not compensate for weak patent or clinical protection.

Key Takeaways

  • Sabarubicin, or MEN 10755, is an investigational anthracycline with historical clinical testing in lung cancer, breast cancer and other solid tumors.
  • No FDA approval, Orange Book listing, active pivotal program or current commercial launch has been established.
  • Biosimilar competition is not relevant because sabarubicin is a small molecule.
  • No material Paragraph IV dispute or generic challenge is apparent.
  • Historical patent protection may have aged substantially, and a current enforceable estate is not established.
  • Commercial value depends on a restart supported by new data, particularly evidence of lower cardiotoxicity or activity in a treatment-resistant population.
  • Without clinical redevelopment, near-term revenue is effectively zero.
  • The most plausible commercial strategy is a focused oncology indication, not broad replacement of established anthracyclines.

FAQs

Is sabarubicin approved by the FDA?

No. Sabarubicin is not identified as an FDA-approved drug and has no established marketed indication.

Is sabarubicin a biosimilar?

No. Sabarubicin is a synthetic small-molecule anthracycline, not a biologic and not a biosimilar.

What is the development code for sabarubicin?

The principal historical development code is MEN 10755.

Can a generic company launch sabarubicin now?

There is no conventional generic launch pathway because no approved sabarubicin reference product has been established. A future sponsor would first need regulatory approval.

Is sabarubicin still being developed for lung cancer?

Publicly available evidence does not establish an active late-stage lung-cancer development program. Historical studies evaluated the candidate in lung cancer, but no current registration strategy has been confirmed.

References

  1. ClinicalTrials.gov. (n.d.). Search results for sabarubicin and MEN 10755. U.S. National Library of Medicine. https://clinicaltrials.gov/

  2. Cvitkovic, E., et al. (2002). Clinical development of sabarubicin, a novel anthracycline derivative. Investigational New Drugs.

  3. European Medicines Agency. (n.d.). Medicines and regulatory information database. https://www.ema.europa.eu/

  4. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/ob/

  5. National Cancer Institute. (n.d.). Drug dictionary: Sabarubicin. https://www.cancer.gov/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.